Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay
Launched by SYSTAGENIX WOUND MANAGEMENT · Dec 12, 2012
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject has presented to participating study site with a wound(s) suspected to be infected, as determined by the Investigator and/ or study staff - defined as one that through clinical judgment has questionable infection status, and /or shows three or more of the NERDS or STONES signs of infection);
- • Subject has presented to participating study site with a wound(s) suspected not to be infected, as determined by the Investigator and/ or study staff - defined as one that does not show three or more of the NERDS or STONES signs of infection.
- • Subject is 18 years of age or older.
- • Subject agrees to complete all aspects of the study and provides Informed Consent
- Exclusion Criteria:
- • Subject is less than 18 years of age.
- • Target wound contains a malignancy
- • Subject has hypersensitivity of the wound or painful wound surface which prevents touching/swabbing of the wound surface.
- • Subject is confirmed to be positive for HIV or hepatitis.
- • Subject is unable or unwilling to provide informed consent.
- • Subjects deemed inappropriate for the study by the site's Principal Investigator.
About Systagenix Wound Management
Systagenix Wound Management is a leading global company dedicated to advancing wound care through innovative products and evidence-based solutions. With a strong focus on enhancing patient outcomes, Systagenix develops and manufactures a comprehensive range of advanced wound dressings and therapeutic technologies. The organization is committed to rigorous clinical research and trials that support the efficacy and safety of its products, ensuring they meet the highest standards in the healthcare industry. By collaborating with healthcare professionals and leveraging cutting-edge science, Systagenix aims to improve the quality of life for patients with complex wounds worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tulsa, Oklahoma, United States
Patients applied
Trial Officials
Tom Serena, MD
Principal Investigator
SerenaGroup, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials